KCM
BIIB icon

Kames Capital Management’s Biogen BIIB Stock Holding History

Kames Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,819
Closed -$1.59M – 165
2014
Q3 		$1.59M Sell
4,819
-4,001
-45% -$1.32M 0.05% 121
2014
Q2 		$2.78M Sell
8,820
-920
-9% -$277K 0.09% 89
2014
Q1 		$2.98M Buy
+9,740
New +$3.09M 0.09% 92

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Kames Capital Management's BIIB Position: Q4 2014 in Review

Kames Capital Management sold out of Biogen (BIIB) in Q4 2014, closing a stake of 4,819 shares — an estimated $1.59M sold.

Kames Capital Management first reported a position in BIIB in Q1 2014 and held it in 3 quarters. The position peaked at $2.98M in Q1 2014. 884 funds tracked by Wall St. Rank hold BIIB as of Q4 2014.

  • Kames Capital Management reported no remaining Biogen position as of Q4 2014 after selling out during the quarter.
  • Kames Capital Management sold 4,819 Biogen shares in Q4 2014, an estimated $1.59M.
  • Kames Capital Management first reported a position in Biogen in Q1 2014 and held it in 3 quarters.
  • Kames Capital Management's Biogen position peaked at $2.98M in Q1 2014.
  • 884 funds tracked by Wall St. Rank held Biogen as of Q4 2014.

Based on Kames Capital Management's 13F filing for Q4 2014, filed 3 Feb 2015.